Furthermore, gain-of-function studies of RUNX2 in prostate cancer cells identified several pro- and antiapoptotic genes differentially expressed in RUNX2-overexpressing cells compared to control cells [23]. This evidence concerns the gene RUNX2 and prostate carcinoma.